康诺亚生物医药科技成都有限公司
CN
 
CN

Scroll

Science & Technology

R&D Center

Keymed Biosciences has established comprehensive R&D platforms in Chengdu and Shanghai, offering all key functions in biopharmaceutical discovery and development process. We have a macromolecular R&D center of 8,000 m2 and a cGMP–compliant pilot-scale workshop of antibody drugs in Chengdu Tianfu International Bio-town, equipped with cutting edge instruments.The cGMP compliant workshop can can support the manufacturing of clinical drugs which comply with the requirement of FDA,EMA and China NMPA.

Antibody Discovery Platform

Integrate advanced high-throughput screening platforms and leverage hybridoma, in vitro display, and single B cell screening techniques to rapidly discover therapeutic antibody candidates.

Proprietary nTCE Bispecific Antibody Platform

nTCE bispecific antibody platform specializes in the design and engineering of bispecific antibodies. This platform has generated three bispecific antibody candidates, including CM355(CD20xCD3), CM336(BCMAxCD3)and CM350(GPC3xCD3).


Process Development Platform

Construct and screen stable high-expressing cell strains, culture and purify cell, develop formulation of finish drug, and transfer from lab to production.

Quality Research Platform

Quality research and control platform features antibody drug characterization, purity and impurity analysis, and bioactivity analysis.

Commercial Manufacturing Platform

Commercial manufacturing park complies with GMP standards of NMPA, FDA and EMA is expected to operate in 2022, providing an additional capacity of 16,000 L. in first phase.

Pipeline

Research areasDrug CandidateTarget(Modality)Focused IndicationsLead
Identification
Pre-ClinicalINDClinical TrialsPartnerCommercial Rights
AutoimmuneCM310IL-4Rα(mAb)Moderate-to-severe AD--Adults

*BTD granted by CDE


Global
Moderate-to-severe AD--Children & Adolescents

Global
CRSwNP

Global
Moderate-to-severe eosinophilic asthma
Global ex mainland
China
CM326TSLP(mAb)Moderate-to-severe AD

Global
CRSwNP

Global
Moderate-to-severe asthma
Global ex mainland
China
COPD
Global ex mainland
China
CM338MASP-2(mAb)IgA nephropathy

Global
OncologyCMG901

*FTD & ODD granted by FDA

Claudin 18.2
(ADC)
Gastric and Other Solid tumors
hz1.pngGlobal
CM313CD38(mAb)RRMM, lymphoma and  other hematological malignancies

Global
SLE

Global
MIL95/CM312CD47
(mAb)
Lymphoma and solid tumors
1638944644511385.pngGlobal
CM355CD20xCD3
(Bispecific)
Lymphoma
hz3.pngGlobal
CM336BCMAxCD3
(Bispecific)
RRMM

Global
CM350GPC3xCD3
(Bispecific)
Solid tumors

Global
CM369CCR8Tumors
hz3.pngGlobal

Swipe left and right to see more

Manufacturing Park

To ensure efficient and timely production of high-quality and affordable antibody drugs, Keymed Biosciences is committed to improving internal production capacity.  A new manufacturing park is under construction and expected to be operated by 2022 to provide an additional capacity of 16,000 L.

Cooperation

Keymed has established strategic cooperation with leading pharmaceutical enterprises to accelerate the R&D progress and jointly explore more possibilities. Through mutual empowerment, we continue to promote the development of next-generation antibody therapies and bring more safe and effective treatments to patients. In the future, the Company will continue to actively seek more like-minded partners.